These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 10745258)

  • 21. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
    Hochhaus A; Lin F; Reiter A; Skladny H; Mason PJ; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Blood; 1996 Feb; 87(4):1549-55. PubMed ID: 8608246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
    Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
    Leukemia; 1997 Apr; 11 Suppl 3():541-4. PubMed ID: 9209451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
    Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
    Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
    Itoh T; Tamura S; Takemoto Y; Kakishita E
    Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-alpha 2a therapy in CML: disappearance of BCR/ABL transcript in a case of long-lasting continuous cytogenetic conversion.
    Pardini S; Addis M; Dore F; Bonfigli S; Nieddu RM; Galanello R; Longinotti M; Pau MG
    Haematologica; 1994; 79(6):540-1. PubMed ID: 7896213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.
    Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S41-4. PubMed ID: 8769700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.
    Martinelli G; Montefusco V; Amabile M; Lemoli RM; Terragna C; Testoni N; Ottaviani E; Rosti G; de Vivo A; Rizzi S; Russo D; Bregoli M; Tura S
    Leuk Lymphoma; 2000 Sep; 39(1-2):113-20. PubMed ID: 10975389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
    Martinelli G; Testoni N; Montefusco V; Amabile M; Saglio G; Ottaviani E; Terragna C; Bonifazzi F; de Vivo A; Pane F; Rosti G; Tura S
    Haematologica; 1998 Jul; 83(7):593-601. PubMed ID: 9718863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
    Hochhaus A; Lin F; Reiter A; Skladny H; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Br J Haematol; 1995 Sep; 91(1):126-31. PubMed ID: 7577619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
    Steegmann JL; Requena MJ; Casado LF; Pico M; Peñarrubia MJ; Ferro MT; Resino M; Fernandez-Rañada JM
    Am J Hematol; 1996 Nov; 53(3):169-74. PubMed ID: 8895687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
    Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman PS; Ku S; Gutterman JU; Talpaz M
    Leukemia; 1992 Aug; 6(8):754-60. PubMed ID: 1640725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
    Colombat M; Fort MP; Chollet C; Marit G; Roche C; Preudhomme C; Reiffers J; Praloran V; Mahon FX
    Haematologica; 2006 Feb; 91(2):162-8. PubMed ID: 16461299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
    Corsetti MT; Lerma E; Dejana A; Basta P; Ferrara R; Benvenuto F; Vassallo F; Abate M; Piaggio G; Parodi C; Sessarego M; Li Pira G; Manca F; Carella AM
    Leukemia; 1999 Jul; 13(7):999-1008. PubMed ID: 10400414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha.
    Reiter A; Marley SB; Hochhaus A; Sohal J; Raanani P; Hehlmann R; Gordon MY; Goldman JM; Cross NC
    Br J Haematol; 1998 Sep; 102(5):1271-8. PubMed ID: 9753056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
    Breccia M; Diverio D; Pane F; Nanni M; Russo E; Biondo F; Frustaci A; Gentilini F; Alimena G
    Leuk Res; 2006 Dec; 30(12):1577-9. PubMed ID: 16630657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.